Edition:
India

People: Zynerba Pharmaceuticals Inc (ZYNE.OQ)

ZYNE.OQ on NASDAQ Stock Exchange Global Market

19.00USD
26 May 2017
Change (% chg)

$0.09 (+0.48%)
Prev Close
$18.91
Open
$18.94
Day's High
$19.09
Day's Low
$18.67
Volume
59,701
Avg. Vol
138,569
52-wk High
$25.95
52-wk Low
$6.31

Anido, Armando 

Mr. Armando Anido is the Chairman of the Board and Chief Executive Officer of the company. Prior to joining the company, Mr. Anido served as the business consultant from May 2014 to October 2014. He has more than 30 years of executive, operational and commercial leadership experience in the pharmaceutical industry. He served as chief executive officer and as a director of NuPathe, Inc., or NuPathe, a publicly-traded specialty pharmaceutical company, from July 2012 through March 2014, during which time he led the company through FDA approval of its lead product, Zecuity, a transdermal patch for migraines. Prior to joining NuPathe, Mr. Anido served as chief executive officer and president and as a director of Auxilium Pharmaceuticals, Inc., or Auxilium, a specialty pharmaceutical company, from July 2006 through December 2011, where he led the company through FDA approval and commercialization of its lead product, Testim, a testosterone gel. He served as a director of Respira Therapeutics, Inc., a pharmaceutical company, from May 2012 through September 2014 and as a director of Adolor Corporation, a pharmaceutical company, from September 2003 through December 2011. Mr. Anido was retired from January 2012 through June 2012. Mr. Anido holds a B.S. in Pharmacy and an MBA, both from West Virginia University.

Basic Compensation

Total Annual Compensation, USD 128,750
Restricted Stock Award, USD 759,066
Long-Term Incentive Plans, USD --
All Other, USD 102,702
Fiscal Year Total, USD 990,518

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --